Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

Core Insights - Adverum Biotechnologies has appointed Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss to its Board of Directors, enhancing its leadership team as it advances its gene therapy candidate Ixo-vec for wet age-related macular degeneration (AMD) [1][2][5] Company Developments - The company is progressing with the LUNA trial for Ixo-vec, which is positioned as a potential best-in-class treatment for wet AMD, aiming to transform the treatment paradigm by offering a long-term solution to preserve sight [2][5] - Dr. Ozden brings over 20 years of experience in ophthalmology drug development, particularly in AAV-based gene therapies, and has previously held leadership roles in other biotech firms [2][3] - Dr. Kiss, a renowned retina specialist, has over 20 years of experience in ocular gene therapy and has been involved in numerous clinical trials, contributing significant expertise to the Board [3][4] Product Focus - Ixo-vec is being developed as a one-time intravitreal injection aimed at treating neovascular or wet AMD, with the goal of reducing the burden of frequent eye injections currently required by standard care [5] - The company aims to leverage its proprietary intravitreal platform to create durable therapies that can be administered in a physician's office, potentially eliminating the need for frequent ocular injections [5]